Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1934 | Informational videos and social media campaigns encouraging cancer screening. Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100834 | Neoplasm of the large intestine HPO | 0.45 |
Navigate: Correlations HPO
There is one clinical trial.
The etiological agent of the current pandemic is a (+)ssRNA virus. SARS-CoV-2 is infecting thousands of people in the world with a fatality rate that varies from 0.1 to 5% in affected countries, thereby causing enormous economic losses. Few antibiotics have shown any efficacy in their combat, but have not yet proven adequate to stop the spread of the disease, nor are there any approved vaccines at the moment. From experiments in plants ongoing infections by RNA viruses, using thermotherapy, which is the application of heat at a temperature between 35-43 °C, the investigators know that raising the temperature affects the transcription of viral proteins due to the formation of small RNA molecules that interrupt the replication process by grouping in specific regions of the RNA molecule, preventing and inhibiting transcription. These small molecules are called small interfering RNAs (siRNAs). This feature has been used through thermotherapy in humans to combat the rapid replication of cells (i.e. cancer cells), attack cells infected by RNA viruses, and in the treatment of some parasitic infections.There are various commercially available devices for thermotherapy use in humans; they are mainly being used to ease muscle pain. They work by increasing the temperature in the range recommended for thermotherapy in humans 39-43 ° C. Therefore, the investigators consider this treatment modality can be used to aid in the elimination of SARS-CoV-2 from the human body, decreasing viral load, which could allow the immune system time for its control and elimination.
Description: Progression to any of the following: Severe COVID-19 - Patient with ≥1 of the following: tachypnea (≥30 breaths per minute), peripheral oxygen arterial saturation (SaO2) less than or equal to 93% (89% in Mexico City and Guadalajara) with a maximum 3 L/min of supplementary oxygen (patients requiring ≥4 L/min will be considered to have progressed to severe COVID-19), or PaO2/FiO2 ratio <300. Critical COVID-19 - Patient with ARDS, shock, multiorgan failure, or any other condition requiring admission to an intensive care unit. Death
Measure: Progression of disease (composite outcome) Time: 28 daysDescription: Proportion of participants deceased by day 15 after enrollment
Measure: Mortality at day 15 Time: 15 daysDescription: Proportion of participants deceased by day 28 after enrollment
Measure: Mortality at day 28 Time: 28 daysDescription: Days from symptom onset to progression to severe COVID-19
Measure: Time to progression to severe COVID-19 Time: Up to 33 daysDescription: Days from symptom onset to progression to critical COVID-19
Measure: Time to progression to critical COVID-19 Time: Up to 33 daysDescription: In-hospital stay in days
Measure: Hospitalization time Time: Up to 33 daysDescription: Ordinal scale of 7 categories: 1) Not hospitalized, without limitations on daily activities; 2) Not hospitalized, with limitations on daily activities; 3) Hospitalized, not requiring supplementary oxygen; 4) Hospitalized, requiring low-flow supplementary oxygen; 5) Hospitalized, requiring supplementary oxygen with high-flow nasal cannula or non-invasive ventilation; 6) Hospitalized, under invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 7) Death
Measure: Percentage of participants at each clinical status in the Ordinal Scale at Day 15 Time: 15 daysDescription: Ordinal scale of 7 categories: 1) Not hospitalized, without limitations on daily activities; 2) Not hospitalized, with limitations on daily activities; 3) Hospitalized, not requiring supplementary oxygen; 4) Hospitalized, requiring low-flow supplementary oxygen; 5) Hospitalized, requiring supplementary oxygen with high-flow nasal cannula or non-invasive ventilation; 6) Hospitalized, under invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 7) Death
Measure: Percentage of participants at each clinical status in the Ordinal Scale at Day 28 Time: 28 daysDescription: Modalities: 1) Simple nasal cannula or face mask; 2) Face mask with reservoir; 3) High-flow nasal cannula; 4) Non-invasive mechanical ventilation; 5) Invasive mechanical ventilation
Measure: Time (days) to last requiring supplementary oxygen according to modality Time: 28 daysDescription: Change in the National Early Warning Score 2 (NEWS-2) with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. This score evaluates 7 parameters (respiratory rate, peripheral arterial oxygen saturation, supplementary oxygen requirements, systolic arterial blood pressure, heart rate, consciousness, and body temperature). Assigned values for every parameter may range from 0 to 3 points, except for supplementary oxygen for which possible values are 0 (not requiring supplementary oxygen) and 2 (requiring supplementary oxygen). The total sum of points for this score may range from 0 to 20 points. Higher scores reflect increasing clinical deterioration.
Measure: Change in National Early Warning Score 2 (NEWS-2) with respect to baseline Time: Days 1, 5, 15, and 28Description: Proportion of patients requiring invasive mechanical ventilation during the entire follow-up period
Measure: Proportion of patients requiring invasive mechanical ventilation Time: 28 daysDescription: Proportion of patients requiring admission to intensive care unit (ICU) during the entire follow-up period
Measure: Proportion of patients requiring admission to intensive care unit (ICU) Time: 28 daysDescription: Days from symptom onset to progression to requiring invasive mechanical ventilation
Measure: Time to requiring invasive mechanical ventilation Time: Up to 33 daysDescription: Days from symptom onset to requiring admission to intensive care unit (ICU)
Measure: Time to requiring admission to intensive care unit (ICU) Time: Up to 33 daysDescription: Severe: Causes death of the patient, puts the patient's life at risk in the moment of occurrence, requires hospitalization or prolongs hospitalization, causes persistent or significant disability. Non-severe adverse events: Do not meet the previously outlined criteria.
Measure: Proportion of patients with adverse events according to outcome Time: 28 daysDescription: Mild (Grade 1): Present with easily tolerated signs and symptoms, do not need specific treatment, do not prolong hospitalization, nor require suspension of the intervention Moderate (Grade 2): Interfere with daily activities (school or work), do not directly threaten life, require specific pharmacological treatment, and do not necessarily require suspension of the intervention. Severe (Grades 3, 4, and 5): Interfere with daily activities (school and work), require pharmacological treatment and suspension of the intervention.
Measure: Proportion of patients with adverse events according to severity Time: 28 daysDescription: Certain Probable Possible Uncertain Unclassifiable
Measure: Proportion of patients with adverse events according to causality Time: 28 daysDescription: Proportion of patients tolerating the intervention (number of sessions and minutes per session).
Measure: Proportion of patients tolerating the intervention (no comparison) Time: 5 daysDescription: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: total leucocytes, neutrophils, lymphocytes, monocytes, and platelets
Measure: Comparison of laboratory parameters with respect to baseline (units: 10^3/microliter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: glucose, urea, blood urea nitrogen, creatinine, total bilirubin, direct bilirubin, and indirect bilirubin.
Measure: Comparison of laboratory parameters with respect to baseline (units: milligrams/deciliter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: hemoglobin, and albumin
Measure: Comparison of laboratory parameters with respect to baseline (units: grams/deciliter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: C-reactive protein
Measure: Comparison of laboratory parameters with respect to baseline (units: milligrams/liter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: D-dimer, and procalcitonin
Measure: Comparison of laboratory parameters with respect to baseline (units: nanograms/milliliter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and creatinine phosphokinase (CPK).
Measure: Comparison of laboratory parameters with respect to baseline (units: International Units/liter) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: neutrophil-to-lymphocyte ratio, and international normalized ratio (INR).
Measure: Comparison of laboratory parameters with respect to baseline (ratio: no units) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: hematocrit
Measure: Comparison of laboratory parameters with respect to baseline (units: percent) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: prothrombin time (PT), and partial thromboplastin time (PTT)
Measure: Comparison of laboratory parameters with respect to baseline (units: seconds) Time: Days 1, 5, 15, and 28Description: Change in laboratory parameters with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized. Parameters to be included are: erythrocyte sedimentation rate (ESR)
Measure: Comparison of laboratory parameters with respect to baseline (units: millimeters/hour) Time: Days 1, 5, 15, and 28Description: Change in cytokine levels with respect to baseline (Day 1), measured at day 5 for all patients, and days 15 & 28 only for patients that remain hospitalized.
Measure: Comparison of cytokine levels with respect to baseline Time: Days 1, 5, 15, and 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports